CD38 and Miyoshi myopathy: Multiple myeloma (MM) treatment has evolved immensely over the past two decades with monoclonal CD38-directed antibodies, immunomodulatory agents, and proteasome inhibition, as cornerstones of MM therapy [1, 2].